Akari Therapeutics, Plc (AKTX) Analysis

This report is auto-generated by an AI stock research platform for informational purposes only. The content is for general information and research reference, and does not constitute financial advice. Data may lag or be incomplete. Always conduct your own research and consult qualified professionals before making any financial decisions. # [Qiltrack AI] Akari Therapeutics PLC (AKTX) 3-Minute Overview > **💡 One-Sentence Summary** > > Simply put, Akari Therapeutics is a tiny, high-risk clinical-stage biotech trying to create a differentiated cancer ADC platform, and the stock is moving more on early science and financing hopes than on any established business today. > **📍 Basic Profile** > > Market Cap **$0.01 billion** · Biotechnology · NASDAQ NMS - GLOBAL MARKET · Price **$18.27** > **⚡ 3 Things You Should Know** > > 1. 🧪 Science story, not business story: The recent stock jump came from promising **preclinical** AKTX-101 data and patent/news flow, which is interesting, but it also means the value here still depends on whether early lab results can survive the long road to human trials. > > 2. 💸 Financing risk is real: AKTX has a **very weak liquidity profile** with a current ratio of just **0.44** and negative cash flow per share, so even if the science looks better, shareholders may still face dilution before the company gets meaningful clinical proof. > > 3. 🎢 Huge volatility cuts both ways: The stock is up sharply from prior levels, but it still sits far below its **52-week high of $56.80**, which tells you this name can re-rate fast on good headlines and collapse just as fast if funding or trial timelines disappoint. > **🎯 Quick Health Check** > > | Dimension | Rating | Details | > |-----------|--------|---------| > | Profitability | Weak👎 | ROE -70.34%, no meaningful commercial earnings base | > | Growth Rate | [Data unavailable] | Clinical-stage biotech; no reliable operating revenue growth data provided | > | Financial Health | Tight🧡 | Current ratio 0.44, negative cash flow, though debt is low | > | Valuation | [Data unavailable] | PE unavailable; stock is trading on pipeline expectations rather than earnings | ### 📋 Layer 2: 2-Minute Deep Dive #### 📊 How Does This Company Make Money? **Business Model in One Sentence:** Oncology drug development assets are advanced for future commercialization or partnership, with value currently tied to pipeline progress rather than product sales. **Revenue Breakdown:** | Business | Share | Trend | Comment | |----------|-------|-------|---------| | Oncology pipeline / AKTX-101 platform | [Data unavailable] | ↑ | Company focus is clearly shifting toward ADC oncology development | | Commercial product revenue | [Data unavailable] | → | No meaningful product revenue data provided; this appears to be a pre-revenue biotech story | **Profitability Metrics:** | Metric | Value | Ranking | Interpretation | |--------|-------|---------|----------------| | Gross Margin | [Data unavailable] | [Data unavailable] | Not very useful here because the company is not being valued on mature product sales | | Net Margin | [Data unavailable] | [Data unavailable] | Loss-making development-stage biotech | | ROE | -70.34% | Below Average | Basically, shareholders' capital is being consumed to fund R&D and operations | --- #### 📈 How's the Growth? **Growth Assessment:** High scientific progress, but commercial growth is **[Data unavailable]** | Metric | Latest | vs Last Year | Trend | |--------|--------|--------------|-------| | Revenue Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Profit Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | **Growth Quality:** > Worth noting: what looks like “growth” here is really **pipeline advancement and market interest**, not business scale. Recent momentum is being driven by preclinical data releases, ASCO abstract acceptance, and patent progress. In other words, this is early-stage value creation, which can be powerful, but it is also fragile because it has not yet been validated by human efficacy data or commercial demand. --- #### 💰 Financial Health Check **One Sentence:** Think of it like a startup with little debt but not enough cash cushion—less like someone buried in loans, more like someone who may need to raise new money soon to keep going. | Metric | Value | Safe Zone | Assessment | |--------|-------|-----------|------------| | Debt Ratio | 2.66% debt-to-equity | <60% safe | ✅Safe | | Current Ratio | 0.44 | >1.5 healthy | 🚨Dangerous | | Cash Flow | Negative ($-15.64/share, TTM) | >0 | 🚨Negative | --- #### 🏷️ Is It Expensive Now? **Price Position (based on 52-week range):** - 52-Week Low: $3.02 - 52-Week High: $56.80 - Current: $18.27, **In the middle**, but still much closer to the low than the high after a big short-term spike | Position Range | Cheap Zone | Fair Zone | Pricey Zone | |----------------|------------|-----------|-------------| | Criteria | 0-33% | 33-66% | 66-100% | | **Current** | ●(28% position) | | | **Valuation Comparison:** | Comparison | Current | Reference | Assessment | |------------|---------|-----------|------------| | vs Own History | PE [Data unavailable] | 5-year avg [Data unavailable] | [Data unavailable] | | vs Peers | PE [Data unavailable] | Industry avg [Data unavailable] | [Data unavailable] | **What the Current Valuation is Betting On:** > The market is basically betting that AKTX-101’s preclinical profile is not just promotional noise—that it can move into Phase 1 on schedule, show differentiated activity, and eventually become valuable enough for a licensing deal, strategic partnership, or much larger oncology rerating. The flip side is harsh: if financing becomes too dilutive or the science weakens in human studies, today’s valuation could still prove too high. --- #### 📰 Any Recent News? | Date | Event | Impact | |------|-------|--------| | 2026-05-21 | AKTX-101 showed synergistic preclinical activity with KRAS inhibitor in pancreatic cancer models | Positive — helped drive the latest stock jump and supports broader platform potential | | 2026-05-20 | Company announced a $5.5M private placement | Negative/Neutral — adds funding, but also reinforces the need for external capital | | 2026-04-21 | ASCO abstract accepted highlighting potential in KRAS mutant tumors | Positive — scientific visibility improved, which matters for a micro-cap biotech | | 2026-04-20 | Positive preclinical data versus leading TROP2 ADCs | Positive — strengthens the “differentiated payload” investment thesis | | 2026-04-08 | Maxim flagged high risk profile due to capital needs | Negative — outside validation that financing risk is a major issue | --- ### 📊 Layer 3: Want More? 3-Minute Complete Analysis #### I. Detailed Financial Data **Profitability Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Gross Margin | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Net Margin | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | | ROE | -70.34% | [Data unavailable] | [Data unavailable] | [Data unavailable] | **Growth Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Revenue Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Profit Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | | EPS Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | --- #### II. Earnings Track Record **Last 4 Quarters vs Expectations:** | Quarter | EPS Expected | EPS Actual | Surprise | |---------|--------------|------------|----------| | 2026-03-31 | -$1.40 | -$1.57 | -11.8% Miss 😟 | | 2025-12-31 | -$1.53 | $0.00 | +100.0% Beat 😀 | | 2025-09-30 | -$3.13 | $0.00 | +100.0% Beat 😀 | | 2025-06-30 | -$4.69 | $0.00 | +100.0% Beat 😀 | **Earnings Trend Interpretation:** The headline beat streak looks better than it really is. For a tiny biotech, EPS often swings because of accounting items, share count changes, or expense timing rather than fundamental operating strength. What you might care about more is that the most recent quarter **missed**, and the company still appears dependent on capital markets rather than self-funded operations. --- #### III. What the Market Thinks **Analyst Ratings:** | Rating | Count | Percentage | |--------|-------|------------| | Strong Buy/Buy | 8 firms | 80% | | Hold | 2 firms | 20% | | Sell | 0 firms | 0% | **Target Price:** [Data unavailable] ~ [Data unavailable] (Median [Data unavailable]) **vs Current Price:** [Data unavailable] **Insider Activity:** Net [Data unavailable] in past 3 months > No insider transaction data was provided. For a micro-cap biotech, insider buying can sometimes signal management confidence ahead of milestones, while insider selling can raise questions—but without the data, we shouldn’t guess. --- #### IV. Key Risk Alerts **3 Risks to Watch:** 1. **Financing Risk:** Current ratio is only 0.44 and the company just raised $5.5M privately → If cash burn continues, it could lead to more dilution and pressure on the stock. 2. **Clinical Execution Risk:** The excitement is based on preclinical AKTX-101 data, not human efficacy yet → If Phase 1 timelines slip or results disappoint, the valuation story can unwind quickly. 3. **Micro-cap Volatility Risk:** With a market cap under $10M and huge daily moves, sentiment can dominate fundamentals → If momentum reverses, price swings could be severe even without major new facts. --- ### 🎬 Summary & Next Steps > **📝 Three-Sentence Summary** > > **What it is:** Akari Therapeutics is a very early-stage oncology biotech built around a novel ADC payload approach, with AKTX-101 now driving the story. > > **Key strength:** The science narrative is getting stronger, with preclinical data, patent progress, and ASCO visibility giving the market a reason to pay attention. > > **Key risk:** The balance sheet looks strained, so the biggest issue is not just whether the drug works, but whether shareholders get diluted heavily before the company reaches meaningful clinical proof. --- > **🔍 Want to Learn More?** > > • Want to know if this company has a strong moat? → Try【Buffett Mode】for deeper analysis > > • Want to check for hidden landmines? → Try【Muddy Mode】for risk screening > > • Is this a growth stock? Want to calculate if it's worth the bet? → Try【Musk Mode】for analysis